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Substantial progress has been made in reduc-
ing human lead exposures in the United
States and elsewhere over the past two
decades. However, many individuals con-
tinue to suffer elevated exposures from envi-
ronmental and occupational sources, and
possibly from the mobilization of skeletal
body stores accumulated over previous peri-
ods of elevated exposures (1–4). The poten-
tial impact of mobilized skeletal Pb stores on
the developing fetus in pregnant women has
been of particular concern because laboratory
and epidemiologic data have indicated that
the developing nervous system is especially
sensitive to perturbations with Pb (5–7).
Studies that have explored the associations
between maternal body Pb burdens and cog-
nitive outcomes in infants postpartum have
generally relied on whole-blood Pb levels as
the biomarker of maternal body Pb burden
and exposure to the developing fetus.
However, the use of blood Pb level as a bio-
marker of exposure has several recognized
limitations, including uncertainty over the
extent to which whole-blood Pb level reﬂects
the toxicologically available fraction of circu-
latory Pb. Several investigators have proposed
that plasma Pb levels may better reflect the
fraction of circulatory Pb that is more freely
available for exchange with tissues, including
the developing fetus (3,8–11). This sugges-
tion is consistent with the toxicokinetic char-
acteristics of readily exchangeable Pb
(9,11,12), and it has also been substantiated
by recent data indicating that plasma
Pb/whole-blood Pb ratios are more strongly
associated with bone Pb levels than are
whole-blood Pb levels (3,13). In light of these
and other observations on plasma Pb levels,
there is a clear need to investigate the role of
plasma Pb levels versus whole-blood Pb as a
predictor of toxicologic outcomes in humans.
Previous studies have reported an appar-
ent severalfold variation in the relative parti-
tioning of Pb between whole-blood and
plasma (or serum) for a given whole-blood
Pb level (3,8,13–19). Because plasma Pb lev-
els appear to be typically < 0.5 ng/mL (i.e.,
< 0.5% of whole-blood Pb levels) in environ-
mentally exposed humans, some of these dis-
crepancies may be explained by methodologic
difﬁculties associated with the collection and
analyses of samples that generally contain
< 1–2 ng total Pb (10). These analytical difﬁ-
culties may introduce variation and bias,
which may confound the assessment of inter-
and intra-individual variation in plasma Pb
levels that may be of toxicologic relevance.
Therefore, we have conducted a longitu-
dinal assessment of the relationship between
Pb in whole blood and plasma in environ-
mentally exposed, reproductive age, non-
pregnant women living in Mexico City,
Mexico. This study was conducted as part of
a larger cohort study that is assessing Pb
kinetics during pregnancy and lactation and
possible associations between maternal body
Pb stores, including bone, blood, and plasma
Pb levels, with adverse outcomes in infant
offspring. These latter assessments are forth-
coming and will be presented elsewhere.
Methods
Study subjects. We recruited 63 healthy
females with no known history of occupa-
tional Pb exposure (mean age, 30.6 years ±
7.2 SD) into the study over a 3-year period
(January 1996 through January 1999), using
two strategies. One called for female volun-
teers who were willing to provide repeated
blood samples over a particular duration.
Using this strategy, we were able to recruit 31
volunteers; among them, 17 provided samples
every week for 4 consecutive weeks, and 14
subjects provided samples every 1–2 months
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Articles
Studies have suggested that plasma lead levels may better reﬂect the toxicologically labile fraction
of circulatory Pb that is more freely available for exchange with target tissues than do Pb levels in
whole blood. Studies have also reported an apparent severalfold variation in the relative partition-
ing of Pb between whole blood and plasma (or serum) for a given whole-blood Pb level. This may
reflect inherent differences in the plasma Pb/whole blood Pb partitioning among individuals
and/or methodologic challenges associated with the collection and analyses of samples that gener-
ally contain < 1–2 ng total Pb. Here, we conducted a longitudinal assessment of the relationship
between Pb in whole blood and plasma in environmentally exposed reproductive-age women (n =
63) living in Mexico City, Mexico. We collected whole blood and plasma samples using trace
metal clean techniques and analyzed them for Pb using high-resolution inductively coupled
plasma mass spectrometry. A subset of subjects provided repeated blood samples weekly for 4
consecutive weeks (n = 17 subjects) or every 1–2 months over a 9-month period (n = 14 subjects).
Plasma Pb concentration was signiﬁcantly positively associated with whole-blood Pb in a curvilin-
ear fashion over the range of blood Pb values observed here (2.13–39.7 µg/dL). This relationship
was best described by the function Plasma Pb = e(–2.392 + 0.0898 × blood Pb), where SEcoefficient =
0.0054, SEconstant = 0.063 (n = 63 subjects, n = 141 observations). Results from the short- and
long-term repeated collection subjects indicated that the within- and between-subject variance
components were not significantly different between the two subsets of subjects. The between-
subjects component accounts for 78% of the variance in plasma Pb levels, while the residual vari-
ance (22%) may be attributed to other unmeasured factors. Collectively, this study demonstrates
that plasma Pb measurements may be applied to general clinical settings, provided that estab-
lished trace metal clean techniques are adopted. This study also shows that the relative (%) parti-
tioning of whole-blood Pb in plasma naturally varies by a factor of about 2–4-fold among subjects
at a given blood Pb level. Because Pb in the plasma is considered to more closely represent the
fraction of Pb in the circulation that is readily exchanged with peripheral target tissues (e.g.,
brain, kidney, skeleton), the routine assessment of plasma Pb may provide a more meaningful
measure of toxicologically available Pb. Key words: blood, human, ICP-MS, lead, plasma. Environ
Health Perspect 110:263–268 (2002). [Online 12 February 2002]
http://ehpnet1.niehs.nih.gov/docs/2002/110p263-268smith/abstract.htmlover a 9-month period. We recruited a sec-
ond sample of 32 subjects from women who
were participating in a cohort study to assess
Pb kinetics during pregnancy and lactation.
The inclusion criteria to participate in the lat-
ter study were not being pregnant at recruit-
ment but intent to get pregnant during the
following year, having no known history of
occupational Pb exposure, and agreeing to
participate in a longitudinal study involving
pregnancy and lactation. Many of the subjects
recruited in the second sample became preg-
nant after their initial recruitment, although
the present study focuses solely on data col-
lected from those subjects prior to their
becoming pregnant. Based on previous stud-
ies with this population, the main risk factors
for Pb exposure in all subjects were residence
in Mexico City for more than 10 years (88%)
and use of Pb-glazed ceramics (58%).
The research protocol was approved by
the Human Subjects Committee of the
National Institute of Public Health of
Mexico; the University of California, Santa
Cruz; and the Harvard University School of
Public Health. All participants received
informed written consent, including a
detailed explanation of the study and proce-
dures used, as well as counseling on ways to
minimize their Pb exposure.
Blood and plasma collection. Trained
medical staff performed all sample collec-
tions at the Center for Environmental
Health Research of the American British
Cordory Hospital, Mexico City, Mexico.
Subjects were instructed beforehand to fast
overnight prior to sample collection. Prior to
venipuncture, each subject’s arm was washed
with ultrapure water and disinfected with
reagent-grade alcohol. Venous blood was
collected using a butterfly catheter (19
gauge) using methods detailed elsewhere
(3,10). Brieﬂy, an initial whole-blood sample
of approximately 3 mL was collected into a
low-Pb container (Vacutainer, B-D 367734;
Becton-Dickinson, Franklin Lakes, NJ) for
total Pb analysis. Subsequently, the catheter
tubing was severed at a point distal to the
venipuncture, and a second whole-blood
sample of 13 mL for plasma separation was
collected via gravity-fed phlebotomy (no
vacuum) into a polyethylene tube containing
100 USP of sodium heparin (H-3393;
Sigma Chemical Company, St. Louis, MO)
and centrifuged at 800 × g for 10 min at
room temperature (10). The 5–6 mL plasma
fraction was then transferred using a poly-
ethylene pipette into a polyethylene bottle
and immediately frozen.
We collected procedural blanks for
plasma collection and processing at the
Center for Environmental Health Research
over the entire 3-year sample collection period
(n = 115 blanks), using methods identical to
those used for the plasma samples. For this,
6–8 mL Milli-Q ultrapure water was added to
the polyethylene centrifuge tube containing
heparin and processed as a plasma sample.
This procedure did not allow assessment of
the butterﬂy catheters for Pb contamination,
but previous work indicated those catheters
contributed negligible amounts of contami-
nant Pb to the sample (10). All samples were
shipped frozen via overnight carrier to the
trace metal facility at the University of
California, Santa Cruz.
All blood collections, plasma and whole-
blood processing, and sample analyses were
conducted under HEPA filtered-air trace
metal clean conditions, and all sample collec-
tion and processing materials (Teﬂon, poly-
ethylene, and polypropylene), except butterﬂy
catheters and Vacutainers for whole blood,
were acid cleaned using procedures detailed
elsewhere (10,20). All reagents, including
water and acids, were high-purity grade.
Sample analyses. We weighed 5–6 mL of
plasma or a 0.5 mL aliquot of whole blood
into a Teﬂon digestion vial and then evapo-
rated and digested it for 8 hr in 3 mL of hot
16 N HNO3; it was then evaporated to dry-
ness and redissolved in 1 N HNO3. We mea-
sured sample Pb and iron (plasma only) levels
independently with a Finnegan Element ICP
high-resolution mass spectrometer (ICP-MS;
Thermo Finnigan, Bremen, Germany) in
multi-isotope counting mode, with both inter-
nal and external standardization (10,21,22).
We used National Institute of Standards and
Technology (NIST; Gaithersbrug, MD)
standard reference materials (SRM) 955
(blood) and 1577 (bovine liver) to evaluate
analytical accuracy. This method yields a
measurement precision of ≤ 0.5% RSD (rela-
tive standard deviation) for Pb concentrations
of > 0.05 ng/mL (10,21). The analytical
detection limit ranged from 0.001 to 0.01
ng/mL, depending on day of analysis.
Assessment of plasma contamination. We
evaluated plasma sample contamination with
Pb by determining the total Pb of procedural
collection and processing blanks and sepa-
rate sample analysis blanks measured over
the 3-year duration of the study. Plasma
hemoglobin and Fe levels were also mea-
sured in order to evaluate the potential con-
tribution of hemolysis to plasma Pb levels.
Previous work suggested that plasma Pb and
total Fe levels may both become abnormally
elevated with hemolysis (10), although more
recent work in our laboratory has suggested
that the wide range of normal plasma Fe lev-
els (e.g., 0.5–2 µg/mL) may limit its use as
an indicator of plasma Pb from moderate
hemolysis. Therefore, we further evaluated
the relative utility of plasma Fe and hemoglo-
bin levels as indicators of Pb contamination
from hemolysis. For this, we split a fresh
plasma sample (15 mL) from a male volun-
teer into three subsamples and spiked with
increasing amounts of hemolysate (e.g.,
0–15 µL) from the separated packed cell vol-
ume, and determined the levels of Pb, Fe,
and hemoglobin in those plasma samples.
We carried out hemoglobin analyses of
plasma samples using an assay based on hemo-
globin catalysis of the oxidation of 3,3´,5,5´-
tetramethylbenzidine by H2O2 (527-A;
Sigma). We centrifuged aliquots of plasma
(0.5 mL) at 3,000 × g for 10 min and analyzed
for hemoglobin following the manufacturer’s
instructions, using a Beckman DU-600 UV-
VIS spectrometer (Beckman Instruments,
Fullerton, CA). We evaluated the sensitivity,
accuracy, and precision of analyses using certi-
fied calibration standards (527-11 and
H3268, Sigma) and repeated analyses of sam-
ples. The hemoglobin assay detection limit
was 2.0 mg/dL, with a sample measurement
reproducibility of 6.6% RSD at sample con-
centrations of approximately 10 mg/dL.
Statistical analysis. Based on univariate
and bivariate summary statistics and distrib-
ution plots for plasma and blood Pb levels,
we loge transformed plasma Pb levels to
improve normality. We explored a number
of models to assess the relationship between
plasma Pb and blood Pb levels. These
included the fit of loge-transformed and
nontransformed plasma Pb versus linear and
higher degree polynomials on whole-blood
Pb using generalized estimating equations
(23). This method took into account the
intrasubject correlation structure due to the
repeated measurements to avoid bias in the
estimation of the standard errors. We
repeated these analyses for the subsample of
subjects whose blood Pb levels were ≤ 10
µg/dL. We chose the best-fit model using
the minimum deviance criteria and the par-
simonious principle and reanalyzed it with
the inclusion of subject age and plasma
hemoglobin and Fe levels as additional vari-
ables to evaluate their possible impact on
plasma Pb levels. We restricted the validity
of the best-fit model to the range of mea-
sured samples to avoid extrapolation outside
the range of observations where the blood
Pb–plasma Pb relationship may deviate from
that predicted by the model. We performed
statistical analyses using STATA (Stata
Statistical Software, release 6.0; Stata
Corporation College Station, TX).
Intersubject versus intrasubject variation
in plasma Pb. We statistically evaluated
between- and within-subject variations in
blood and plasma Pb levels over both short-
term (weeks) and long-term (months) dura-
tions for two reasons: ﬁrst, to assess the extent
that a single plasma and blood Pb measure-
ment per subject predicted the “true” values
for that subject, and second, to determine
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sured (e.g., contamination from hemolysis,
sample processing, etc.) or unmeasured (e.g.,
diet, environmental exposures, etc.) factors
would confound or preclude comparisons
between subjects, or the assessment of tempo-
ral changes in plasma Pb levels over preg-
nancy and lactation, to be conducted in the
larger cohort study. We conducted analyses
using the variance components estimation of
SAS, Version 8 (SAS Institute, Cary, NC). 
Results
Table 1 shows summary statistics for the
subjects and data. Median plasma Pb and
blood Pb levels in this cohort were 0.188
ng/mL and 6.90 µg/dL, respectively, with a
median relative plasma Pb of 0.29% of
whole-blood Pb levels. We excluded a single
sample from one subject from these data and
all statistical analyses due to contamination
of the plasma sample from hemolysis.
Plasma Pb concentrations were signifi-
cantly positively associated with whole-blood
Pb levels in a curvilinear fashion over the range
of blood Pb values observed in our study pop-
ulation (2.13–39.7 µg/dL; Figure 1A). The
best-ﬁt model describing this relationship was
an exponential function of the form Plasma
Pb = e(–2.392 + 0.0898 × blood Pb), where
SEcoefﬁcient = 0.0054 and SEconstant = 0.063 (p
< 0.01, n = 63 subjects, n = 141 observations).
This model explained 71.8% of the variance
in plasma Pb levels. Because the effect of sub-
ject age on blood and plasma Pb levels was not
signiﬁcant, we did not retain it in the model.
We selected this best-ﬁt model because it was
the simplest model that proved equal to or
superior to alternate polynomial models, based
on model results and quantile–quantile nor-
mal plots of the model residuals.
To evaluate whether the blood Pb–plasma
Pb relationship reported above was signifi-
cantly inﬂuenced by the presence of the sub-
jects with elevated blood Pb levels, we assessed
a series of models for the subsample of sub-
jects whose blood Pb levels were ≤ 10 µg/dL.
As with the entire data set, the analysis of the
quantile–quantile normal plots of the model
residuals indicated that the same general
exponential model selected above provided
the best ﬁt for this subset of subjects (n = 48
subjects, n = 104 observations): Plasma Pb =
e(-2.383 + 0.081 × blood Pb), where SEcoefficient =
0.018 and SEconstant = 0.114 (p = 0.012;
model explains 22% of the variance in plasma
Pb levels; Figure 1B).
The relative partitioning of Pb in plasma
(plasma Pb expressed as a percentage of
whole-blood Pb) varied from 0.099% to
0.74% over the full range of blood Pb levels
observed here. Interestingly, the data suggest a
nonlinear U-shaped relationship between
whole-blood Pb levels and percentage plasma
Pb (Figure 2). The best-ﬁt nonlinear regres-
sion to these data shows a signiﬁcant negative
slope relationship between whole-blood Pb
and percent plasma Pb for subjects with
blood Pb levels between about 2 and 10
µg/dL [p < 0.001; b = –0.0198 ± 0.0043 SE;
95% confidence interval (CI), –0.0283 to
–0.0113], and a signiﬁcant positive slope for
this relationship in subjects with blood Pb
levels > 10 µg/dL (p < 0.001; b = 0.011 ±
0.0023 SE; 95% CI, 0.0062–0.0159).
However, this latter (positive) slope appears to
be statistically unstable, because it is driven
heavily by the two subjects with blood Pb lev-
els > 25 µg/dL. If those two subjects are
excluded, the slope of the regression for sub-
jects with blood Pb levels > 10 µg/dL is not
signiﬁcantly different from zero (p = 0.216; b
= 0.0066 ± 0.0053 SE; 95% CI, –0.0039 to
0.0171). All of the above regression models
were adjusted for the repeated measurements
structure of the data.
Subject variation in plasma Pb levels.
Statistical analyses of data from the short- and
long-term repeated collections (Figure 3)
shows that the variance components (i.e.,
within and between subjects) were not signiﬁ-
cantly different in the short-term compared to
the long-term subject data sets. Therefore, we
pooled and reanalyzed data for both the
short- and long-term repeat collections. Those
results showed that the between-subjects com-
ponent accounts for 78% of the variance in
plasma Pb levels, whereas the residual vari-
ance of 22% may be attributed to other
unmeasured factors. Further, analyses that
included the variables plasma hemoglobin
and Fe showed that these variables did not
contribute significantly to the within- or
between-subject variance in plasma Pb levels.
By comparison, the between subjects and
residual components account for 83% and
17% of the variance in whole-blood Pb levels,
respectively.
We evaluated the effect of season on
plasma and blood Pb levels using the com-
bined repeated collection data set. For this,
we coded the sample collection date as either
rainy (June–September) or dry (October–
May) season and analyzed in a univariate
(plasma Pb) or bivariate (plasma and blood
Pb) model. The effect of season on plasma
Pb levels was marginally nonsignificant in
the univariate model (p = 0.06), with plasma
Pb levels tending to be slightly higher during
the dry season (0.11 ng/mL; 95% CI,
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Table 1. Descriptive summary values for the subjects, including plasma Pb, whole-blood Pb, and plasma
hemoglobin and total Fe levels. 
Median 
Category Meana (blk corr)b SD Min Max
All subjects (n = 63)
Subject age (years) 30.6 30.0 7.20 17 51
Plasma Pb (ng/mL) 0.317 0.188 (0.183) 0.448 0.060 2.65
Blood Pb (µg/dL) 9.22 6.90 (6.90) 7.29 2.13 39.7
Plasma/whole-blood Pb ratio (%) 0.308 0.290 (0.285) 0.107 0.099 0.736
Plasma hemoglobin (mg/dL) 3.32 3.61  1.32 < DL 9.51
Plasma total Fe 0.937 0.971  0.236 0.400 1.34
Subset of subjects (blood Pb ≤ 10 µg/dL; n = 48)
Plasma Pb (ng/mL) 0.165 0.151 (0.147) 0.064 0.060 0.290
Blood Pb (µg/dL) 5.94 5.67 (5.67) 2.13 2.13 10.1
Plasma/whole-blood Pb ratio (%) 0.291 0.281 (0.270) 0.087 0.099 0.480
Plasma hemoglobin (mg/dL) 3.20 3.42 1.30 < DL 6.89
Plasma total Fe  0.935 0.959 0.211 0.542 1.31
Abbreviations: DL, detection limit; Max, maximum; Min, minimum.
aData calculated using a single value per subject; when multiple values per subject were available, those values were
averaged into a single value for calculation in these summary data. bPlasma values corrected for the sample collection
and processing Pb blank (mean = 0.024 ng Pb; see text for details). 
Figure 1. Whole-blood Pb versus plasma Pb concentrations (ng/mL) for (A) all subjects (n = 63 subjects; n =
141 observations) and (B) subjects with whole-blood Pb levels ≤ 10 µg/dL (n = 48 subjects; n = 104 observa-
tions). Curves indicate the best-ﬁt models to the observations: (A) Plasma Pb = e(–2.392 + 0.0898 × blood Pb) and
(B) Plasma Pb = e(–2.383 + 0.081 × blood Pb) (see text for details).
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A B–0.005 to 0.23). However, this small effect
was attenuated when we included blood Pb
levels in the model (p = 0.18).
Assessment of plasma Pb contamination.
The sample collection/processing Pb blanks
measured here averaged 0.024 ng Pb (±
0.002 SE; median, 0.015 ng Pb; range,
0.003–0.091 ng Pb; n = 115). Sixty-five of
the measured blanks were below the analyti-
cal detection limit, yielding calculated mean
levels of 0.012 ng Pb ± 0.001 SE (median,
0.013 ng Pb; range, 0.003–0.022 ng Pb;
blank values calculated using 0.5 detection
limit for the respective analysis days). The
remaining 50 blanks that were above the
detection limit yielded mean levels of 0.040
ng Pb ± 0.003 SE (median, 0.034 ng Pb;
range, 0.009–0.092 ng Pb). Although blank
Pb levels were well characterized here, we
did not perform quantitative correction of
plasma Pb concentrations from external Pb
contamination because there is no reliable
method to determine the relative contribu-
tion of blank contaminant Pb to the plasma
fraction of whole blood (10). Some fraction
of blank Pb undoubtedly partitions with the
separated plasma fraction, though the
amount is likely small and may vary with the
physiochemical nature of the Pb and other
biologic and physical factors (8).
Nonetheless, we conducted an exercise in
which we corrected the plasma sample Pb
levels for the measured sample collection/
processing blank to conservatively demon-
strate the small impact that plasma sample
contamination may have had on the values
reported here. For this exercise, we subtracted
the mean total procedural blank value (0.024
ng Pb) from the amount of plasma sample
Pb (nanograms) using the formula 
Plasma [Pb]corrected = {(Plasma [Pb]uncorrected
× plasma sample volume) – blank Pb}
÷ plasma sample volume,
where the units for the [Pb], plasma sample
volume, and blank Pb were nanograms per
milliliter, milliliter, and nanograms Pb,
respectively. The small difference between
the corrected versus uncorrected plasma Pb
levels (mean difference, –2.74% ± 0.14 SE;
median, –2.46%; range, –0.16% to –8.95%)
demonstrates that the low blanks measured
here would in general have a small effect on
the plasma Pb values (Table 1). Further, to
ensure that the derived best-fit model
describing the blood Pb–plasma Pb relation-
ship (Figure 1) was not biased by uncor-
rected sample Pb contamination, we
performed the best-ﬁt model analyses using
the blank corrected plasma Pb data. The
model derived from this exercise was statisti-
cally indistinguishable from the best-fitted
model using the uncorrected plasma Pb data
reported above (data not shown).
We attributed the apparent plasma Pb
contamination in a single sample from one
subject to lysis of erythrocytes during sample
collection and processing, based on a mea-
sured plasma hemoglobin level of 20 mg/dL.
Otherwise, there was no discernable plasma
contamination from hemolyzed erythrocytes
in any of the remaining samples, as suggested
by the normal range in measured plasma
hemoglobin and total Fe levels (Table 1). The
exercise where we intentionally spiked
plasma samples from a male volunteer with
hemolysate shows a clear relationship
between elevated plasma hemoglobin and
plasma Pb levels (Figure 4), thereby substanti-
ating the exclusion of the above plasma sam-
ple from this study. Those results also suggest
that plasma hemoglobin levels may be more
diagnostic than plasma total Fe levels for the
assessment of plasma contamination from
hemolysis, based on the linear 11-fold
increase in plasma hemoglobin levels in those
samples, compared to the lower 2.4-fold
increase in plasma total Fe levels.
In light of the above results, we explored
whether variation in plasma hemoglobin lev-
els could explain some of the variance in
plasma Pb levels in the study subjects, under
the assumption that mild hemolysis could
contribute to increasing plasma Pb levels
without discernibly increasing plasma hemo-
globin levels. We conducted this analysis by
including hemoglobin levels in the longitudi-
nal models for the short-term and long-term
repeat collection subjects. The results indicate
that variation in hemoglobin levels do not
measurably contribute to variation in plasma
Pb levels (p = 0.56), further substantiating
that hemolysis was an unimportant contribu-
tor to plasma Pb levels in the present study.
Discussion
Relationship between plasma Pb and whole-
blood Pb. We observed a strong curvilinear
relationship between plasma Pb and whole-
blood Pb levels across the range of blood Pb
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Figure 2. Whole-blood Pb versus plasma Pb
expressed as a percentage of whole-blood Pb
levels for all subjects (n = 63 subjects; n = 141
observations). The solid line indicates the best-ﬁt
regression with a Lowess smoothing. (See
“Results” for regression parameters.)
Figure 3. (A) Plasma Pb concentrations (ng/mL) and (B) corresponding plasma Pb expressed as the percent
of whole-blood Pb in subjects sampled repeatedly over short-term durations (n = 17 subjects); samples
within subjects were collected at weekly intervals over 3–4 consecutive weeks between April 1998 and
January 1999. (C) Plasma Pb concentrations (ng/mL) and (D) corresponding plasma Pb expressed as the
percent of whole-blood Pb in subjects sampled repeatedly over long-term durations (n = 14); samples
within subjects were collected at 1–2 month (mo.) intervals. The numbers above each set of bars indicates
the total interval over which all samples were collected for each subject. 
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.levels encountered in these non-occupation-
ally exposed women (2.13–39.7 µg/dL;
Figure 1). These data indicate that “typical”
plasma Pb levels in this population are
approximately 0.29% (median) of whole-
blood Pb levels and always < 0.5% of whole-
blood Pb when the latter are < 25 µg/dL.
However, the relative fraction of whole-
blood Pb contained in the plasma varied
greatly among subjects, ranging from
0.099% to 0.74% across all subjects and
from 0.099% to 0.48% for subjects with
blood Pb levels ≤ 25 µg/dL (Table 1, Figure
2). This suggests that the fraction of Pb par-
titioning in plasma may serve as a superior
alternative to whole-blood Pb levels for
assessing the toxicodynamics of Pb (11).
The relative partitioning of Pb in plasma
(percentage plasma Pb) increases with decreas-
ing blood Pb levels of 10 µg/dL or lower,
based on the significant negative regression
slope for blood Pb levels around 2–10 µg/dL
(Figure 2). This interesting relationship, which
has not been reported previously, supports
that Pb partitioning between plasma and non-
plasma components is composed of a relatively
high affinity but very low capacity specific
binding component in the plasma, and a rela-
tively lower afﬁnity but high capacity binding
component in the nonplasma fraction (e.g.,
erythrocytes). This conceptual competitive
binding model is consistent with the relatively
shallow slope of the blood Pb–plasma Pb con-
centration regression at low blood Pb levels
(Figure 1). It also suggests that the partitioning
of Pb in the nonplasma fraction may serve a
somewhat protective role in terms of Pb avail-
ability to tissues outside the circulation, by
limiting the relative amount of Pb in the
plasma fraction as blood Pb levels increase
toward 10 µg/dL. We do not believe that this
observation is due to disproportionately higher
blank Pb contamination at the lower plasma
Pb levels because the estimated plasma Pb
blank correction (~0.2 ng Pb) needed to elimi-
nate the statistically signiﬁcant negative slope
is nearly eight times the actual mean sample
collection/processing Pb blank measured here
(0.024 ng Pb).
The best-ﬁt model to the blood Pb versus
plasma Pb concentration data does not pre-
dict a plasma Pb level of zero at a blood Pb
level of zero (Figure 1). This further suggests
that the relationship between blood and
plasma Pb levels is different at very low blood
Pb levels than that observed over the range of
blood Pb levels reported here. Both Bergdahl
et al. (24) and Hernandez-Avila et al. (3)
similarly suggested that the relationship
between blood Pb versus plasma Pb derived
from occupationally and environmentally
exposed subjects may not extrapolate to
lower blood Pb levels. Bergdahl et al. (24)
also suggested that the presence of a system-
atic error in their measurement of plasma Pb
levels may account for their reported regres-
sion intercept of 0.2 ng Pb/mL plasma at a
blood Pb of zero. It is unlikely that the pres-
ence of a systematic error significantly con-
tributed to our observations because we
would need a plasma sample analytical bias
on the order of 0.50 ng Pb here to account
for the plasma Pb intercept of approximately
0.09 ng/mL at a blood Pb of zero (given an
average plasma volume for analysis of 5.7 mL
± 0.09 SE). This value is more than 20 times
higher than the mean total procedural Pb
blank in this study. Moreover, previous stud-
ies in our laboratory intercalibrating the ICP-
MS method used here with isotope dilution
thermal ionization mass spectrometry
(TIMS) have not suggested the presence of a
systematic bias for low Pb concentration
measurements (21,22,25).
Comparisons with previous studies. Several
studies have investigated the relationship
between plasma (or serum) Pb and whole-
blood Pb levels in environmentally and occu-
pationally exposed subjects. For example, we
previously reported plasma Pb levels in a small
(n = 26) cohort of adult subjects with no his-
tory of occupational Pb exposure, using sam-
ple collection and analysis methods identical
to those reported here. That cohort exhibited
slightly higher median plasma Pb (0.27
ng/mL) and blood Pb (7.34 µg/dL) levels and
a very similar curvilinear relationship between
plasma Pb and blood Pb levels over the range
of reported blood Pb values (2.3–42 µg/dL).
Generally similar curvilinear relationships
between plasma (or serum) Pb and whole-
blood Pb levels have also been reported by
deSilva (14), Manton and Cook (8), Schutz et
al. (19), and Bergdahl et al. (24), which collec-
tively substantiate the relative increase in the
partitioning of whole-blood Pb into plasma as
blood Pb levels increase above 25 µg/dL.
However, further direct comparison with
those latter studies is difﬁcult in most if not all
cases because the researchers used different
methods of sample collection and analysis,
including varying degrees of sample contami-
nation control, as well as study populations
that vary widely in size and Pb exposure his-
tory, among other factors. Further, while
plasma and serum samples are considered
interchangeable regarding their relative Pb
content, this has not been systematically vali-
dated within a sufﬁcient number of subjects.
Subject variation in plasma Pb levels.
This study was unique in that we performed
repeated plasma and blood Pb collections
from a subset of subjects, in order to better
evaluate variation in plasma Pb levels both
within and between subjects (Figure 3). A
primary benefit of this exercise was its
demonstration that the within-subject vari-
ance in plasma Pb levels was small relative to
the between-subject variance, regardless of
whether the repeat collections occurred over
weeks or months. This substantiates that the
plasma and whole-blood Pb measurements
were highly reproducible within a subject
and that a single plasma or whole-blood Pb
measurement is a relatively good predictor of
those values for an individual when com-
pared to the variance in those values across
the study population.
The residual variance in plasma Pb levels
(22%) that could not be explained by the
between-subjects component (78% variance
explained) may be attributed to other factors
that may affect plasma Pb levels. These may
include unmeasured temporal differences in
diet and Pb exposure, different bone Pb bur-
dens, slight differences in sample collection
and processing, and so forth. However, we
cannot attribute it to variation in subject
age, season of sample collection, or whole-
blood hemolysis during collection because
those factors did not contribute signiﬁcantly
to the variance in plasma Pb levels when we
included them in the statistical models.
Implications for Pb toxicodynamics and
widespread application of plasma Pb mea-
surements. As we noted above, these data
demonstrate that the relative (%) partitioning
of whole-blood Pb in plasma naturally varies
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Figure 4. Relationship between (A) plasma hemoglobin and plasma Pb and between (B) total plasma Fe
and plasma Pb levels in subjects and in a male volunteer whose collected plasma was spiked with
increasing amounts of hemolysate from packed cells following whole-blood centrifugation. The solid line
is the best-ﬁt linear regression for the male volunteer plasma samples only: (A) slope = 0.0133, y-intercept
= –0.108, r = 0.9995; (B) slope = 0.0427, y-intercept = –0.854, r = 0.9977.
1.50
1.25
1.00
0.75
0.50
0.25
0.00
P
l
a
s
m
a
 
P
b
 
(
n
g
/
m
L
)
02 0 0 5 1234
Hemoglobin (mg/dL)
P
l
a
s
m
a
 
P
b
 
(
n
g
/
m
L
)
Plasma Fe (µg/mL)
40 60 80 100 120
B 1.50
1.25
1.00
0.75
0.50
0.25
0.00
A Subjects
Male volunteer
Hemolysatebetween subjects by a factor of about 2- to 4-
fold at a given blood Pb level (Figure 2).
Because Pb in the plasma is considered to
more closely represent the fraction of Pb in
the circulation that is readily exchanged with
peripheral target tissues (e.g., brain, kidney,
skeleton) (3,11,12,26), the routine assess-
ment of plasma Pb may provide a more
meaningful measure of toxicologically avail-
able Pb. This has been suggested previously
(11) and also has been substantiated by stud-
ies showing a stronger statistical association
between bone Pb levels and plasma Pb/whole
blood Pb ratios, compared to bone Pb and
blood Pb levels (3,13). In light of this fact,
the routine assessment of plasma Pb levels
should be considered a marker of bioavailable
Pb in clinical and laboratory studies of Pb
toxicity and toxicodynamics. Those measure-
ments would complement blood Pb level
measurements because the latter provide a
relatively longer time-integrated measure of
Pb exposure from exogenous and endoge-
nous sources (3,11,27–29).
This study also substantiates the poten-
tial utility of plasma Pb measurements in our
ongoing investigations of bone Pb toxicody-
namics in response to increased physiologic
stressors on bone metabolism, such as preg-
nancy, lactation, and nutritional deﬁciency.
As we noted above, initial studies have
shown a significant relationship between
bone Pb levels and the plasma Pb/whole
blood Pb ratio (3). However, this observa-
tion may also reﬂect inherent differences in
the partitioning of Pb between plasma and
whole blood and its effect on bone Pb levels,
rather than a specific mobilization of bone
Pb into plasma per se. Consistent with this,
a recent study by Gulson et al. (30) report-
ing stable Pb isotopic compositions in blood
and spot urine samples collected from
women over the course of pregnancy sug-
gested that Pb released from the skeleton was
not preferentially partitioned into plasma.
That study was limited in that it used urine
Pb as a surrogate of plasma Pb, and the iso-
topic composition of the labile fraction of
skeletal Pb was not well known in those sub-
jects. Thus, additional research using direct
and repeated measurements of plasma Pb
over the course of pregnancy would be desir-
able. Nonetheless, it remains apparent that
even if plasma Pb/whole blood Pb ratios did
not change over the course of pregnancy,
measurements of plasma Pb levels at least
one time during pregnancy may provide a
measure of Pb exposure to the developing
fetus that is more predictive of toxicity than
whole-blood Pb levels. To address this, stud-
ies now under way will specifically explore
the association between maternal plasma Pb
levels over pregnancy and neurobehavioral
outcomes in infant offspring.
The plasma sample collection procedures
we used here may be applied to general clinical
settings, provided that well-established trace
metal clean techniques are adopted in sample
collection and analyses. These procedures were
developed in previous methodologic studies
(3,10) which indicated that the sample collec-
tion methods used here were robust and not
susceptible to errors associated with sample
collection. This study also demonstrates that
the ICP-MS method used here possesses the
sensitivity for Pb measurements necessary for
quantitation of Pb in plasma of environmen-
tally exposed subjects. The wide availability of
ICP-MS instrumentation, in contrast to more
sophisticated mass spectrometers such as mul-
ticollector ICP-MS or TIMS, should favor
more routine assessments of plasma Pb levels
within clinical settings.
Future studies. Future assessment of the
blood Pb versus plasma Pb relationship at
blood Pb levels approaching zero may be of
fundamental interest because the lowest blood
Pb level reported here (2.13 µg/dL) and aver-
age current adult blood Pb levels in the United
States (~2 µg/dL) (1) are still > 100-fold
higher than estimated blood Pb levels in prein-
dustrial humans (~0.016 µg/dL) (31,32). This
may be facilitated using specially reared animal
models to assess the relationship between
plasma Pb and blood Pb across ranges of
blood Pb levels that more closely approximate
preindustrial levels. The feasibility of these
studies has already been shown (20).
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